The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 March 2026•

1 min read

Evercore Upgrades DexCom to Outperform, Citing Strong Growth Outlook Through 2028

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

Key Facts

1Evercore ISI upgraded DexCom (DXCM) to Outperform from In Line and set a $90 price target.

2Evercore expects double-digit revenue growth and more than 200 basis points of annual margin expansion through 2028.

Evercore ISI has upgraded DexCom (DXCM) from In Line to Outperform, setting a new price target of $90 per share. The upgrade is supported by expectations of double-digit revenue growth and annual margin expansion exceeding 200 basis points through 2028. Analysts estimate the company’s earnings per share (EPS) will achieve a compound annual growth rate of approximately 25% based on the new projections. Key drivers for this optimistic outlook include advancements in automated delivery systems and expanded coverage for non-insulin-treated Type 2 diabetes. Evercore highlighted the potential for significant operational leverage as a primary catalyst for the rating change. This positive assessment positions DexCom as a strong contender in the medical devices sector over the next several years.